|
|
Atypical molecular background of glioblastoma and meningioma developed
in a patient with Li–Fraumeni syndrome Piotr Rieske, Magdalena Zakrzewska,
Wojciech Biernat, Jacek Bartkowiak,
Arthur Zimmermann and Paweł Piotr
Liberski
Department of Molecular Pathology and
Neurology, Chair of Oncology [P.R., M.Z. P.P.L.]; Department of Tumor Pathology, Chair of
Oncology [W.B.]; Department of Medical Biochemistry,
Institute of Physiology and Biochemistry [J.B.], Medical University of Lodz, Lodz, Poland.
Institute of Pathology, Division of
Surgical Pathology, University of Bern, Switzerland [A.Z.]. Pawel Piotr Liberski, Czechoslowacka st.
8/10, 92-216 Lodz, Poland [P.P.L].
Correspondence to: Paweł Piotr
Liberski, Email: ppliber@csk.am.lodz.pl, Phone: +48-42-679-1477, Fax: +48-42-679-1477.
We observed three neoplasms with completely different histologies:
malignant fibrous histiocytoma (MFH), atypical meningioma (AM), and
glioblastoma (GB), developing in a patient with Li–Fraumeni
syndrome.
By using a combined molecular approach we performed
molecular characterization of all three tumours.
Data obtained showed
an interesting molecular background of the AM and GB.
AM showed TP53 mutations
and a 22q loss of heterozygosity (LOH).
GB showed epidermal growth
factor receptor (EGFR) amplification and TP53 mutations,
whereas P16, PTEN, Rb were intact in terms of LOH and/or
multiplex PCR (polymerase chain reaction) analysis.
Additionally, GB
has a 1q LOH, which is an extremely rare alteration in glioblastomas.
Identical 1q LOH was also observed in MFH.
Keywords: glioblastoma - Li–Fraumeni
syndrome - malignant fibrous histiocytoma - meningioma - TP53
© Springer 2005
Source: http://springerlink.metapress.com/openurl.asp?genre=article&eissn=1573-7373&volume=71&issue=1&spage=27
DOI: http://dx.doi.org/10.1007/s11060-004-9181-3
|
